Tibet Pharmaceutical announced that the company plans to repurchase shares through centralized bidding, with an amount not less than 170 million yuan and no more than 200 million yuan. The repurchase price is not more than 55 yuan/share. It is expected to repurchase 30909.09 million shares to 36363.64 million shares, accounting for 0.96%-1.13% of the total share capital. The capital comes from its own capital. Shares are repurchased for equity incentives or employee stock ownership plans, and will be cancelled if the transfer is not completed within 3 years. The buyback was not more than 12 months since it was reviewed and approved by the board of directors, supervisors, controlling shareholders, etc. with no plans to reduce their holdings for the next 3 or 6 months. The company believes that the repurchase will not have a significant impact on operations, etc.

Tibet Pharmaceutical announced that the company plans to repurchase shares through centralized bidding, with an amount not less than 170 million yuan and no more than 200 million yuan. The repurchase price is not more than 55 yuan/share. It is expected to repurchase 30909.09 million shares to 36363.64 million shares, accounting for 0.96%-1.13% of the total share capital. The capital comes from its own capital. Shares are repurchased for equity incentives or employee stock ownership plans, and will be cancelled if the transfer is not completed within 3 years. The buyback was not more than 12 months since it was reviewed and approved by the board of directors, supervisors, controlling shareholders, etc. with no plans to reduce their holdings for the next 3 or 6 months. The company believes that the repurchase will not have a significant impact on operations, etc.